Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 144-152

  Kew, Michael C ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Apoptosis; Carboxy terminal truncation; Epigenetic modification; Hepatitis B virus; Hepatitis B virus x gene and protein; Hepatocellular carcinoma; Insulin like growth factor II; Nuclear excision repair; Telomerase

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; METHYLTRANSFERASE; PROTEIN P53; SOMATOMEDIN; TELOMERASE; VIRUS DNA;

APOPTOSIS; CANCER GROWTH; CELL CYCLE PROGRESSION; DNA METHYLATION; ENZYME INHIBITION; EPIGENETICS; EXCISION REPAIR; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 78650769017     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06546.x     Document Type: Review

References (100)

1. Kew MC. Epidemiology of hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol. Biol. (Paris). 2010; 58: 273-7.
2. Robinson WS. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu. Rev. Med. 1994; 45: 297-301.
3. Paterlini P, Poussin K, Kew MC et al. Selective accumulation of the x transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21: 313-21.
4. Murakami S. Hepatitis B virus x protein: a multifunctional viral regulator. J Gastroenterol. 2001; 36: 651-60.
5. Miller RH, Robinson WS. Common evolutionary origin of hepatitis x virus and retroviruses. Proc. Natl. Acad. Sci. U S A 1986; 83: 2531-5.
6. Caselmann WH, Koshy R. Transactivators of HBV, signal transduction and tumorigenesis. In: Caselmann WH, Koshy R, eds. Hepatitis B Virus: Molecular Mechanisms in Disease and Novel Strategies for Therapy. London: Imperial College Press, 1998; Vol. 1. 161-81.
7. Feitelson MA, Duan LX. Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Oncogene 1997; 150: 1141-57.
8. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2007; 252: 157-70.
9. Diao J, Garces R, Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev. 2001; 12: 189-205.
10. Seifer M, Hohne H, Schaefer S et al. In vitro tumorigenicty of hepatitis B virus DNA and HBx protein. J Hepatol. 1991; 13: S61-5.
11. Kim YC, Song KS, Yoon G et al. Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx mediated apoptosis. Oncogene 2001; 20: 16-23.
12. Miyake M, Sato C, Gotanda T et al. Integration of region x of hepatitis B virus genome in human primary hepatocellular carcinomas propagated in nude mice. J. Gen. Virol. 1986; 67: 1449-54.
13. Kim CM, Koike K, Saito I et al. HBx gene of hepatitis B virus induces liver cancer in nude mice. Nature 1991; 351: 317-20.
14. Slagle BL, Lee TH, Medina D et al. Increased sensitivity to the carcinogen, diethylnitrosamine, in transgenic mice carrying the hepatitis B virus x gene. Mol. Carcinog. 1996; 15: 261-9.
15. He Y, Sun HQ, He XE et al. Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells. Med. Oncol. 1 December 2009. epub.
16. Herman JG, Baylin SP. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003; 349: 2042-54.
17. Chen T, Li E. Structure and function of eukaryotic DNA methyl transferases. Curr. Top. Dev. Biol. 2004; 60: 55-89.
18. Yang B, Guo M, Herman JG et al. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 2003; 163: 1101-7.
19. Lee JO, Kwun HJ, Jung JK et al. Hepatitis B virus x protein represses E-Cadherin expression via activation of DNA methyl transferase 1. Oncogene 2005; 24: 6617-25.
20. Liu J, Lian Z, Han S et al. De-regulation of E-Cadherin by hepatitis B virus x antigen in hepatocellular carcinoma. Oncogene 2006; 16: 1008-17.
21. INK4A-cyclinD1-CDK 4/6-pRb-E2F1 pathway. Cancer Res. 2007; 67: 5771-8.
22. 16INK4 hypermethylation with hepatitis B virus x protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol. Int. 2007; 57: 326-36.
23. INK4A promoter via DNA methyl transferases in the early stage of HBV-associated hepatocarcinogenesis. J. Viral Hepat. 2010; 17: 98-107.
24. INK4A-cyclin D1-CDK 4/6-Rb-2EF1 pathway. Cancer Res. 2007; 12: 5771-8.
25. Park IN, Sohn BH, Yu E et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus x protein. Gastroenterology 2007; 132: 1476-94.
26. Zheng DL, Zhong L, Cheng A et al. Epigenetic modification induced by hepatitis B virus-protein via interaction with de novo methyl transferase DNMT3A. J. Hepatol. 2009; 30: 377-87.
27. Samuels-Lev Y, O'Connor DJ, Bergamaschi D et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cells 2001; 8: 781-94.
28. Zhao J, Wu G, Bu F et al. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-conrtaining, and proline-rich-region-containing protein 1 (ASPP1) and ASPP2 genes promotes tumour growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 2010; 51: 142-53.
29. Jung JK, Park SH, Jang KL. Hepatitis B virus x protein overcomes the growth inhibitory potential of retinoic acid by down-regulating retinoic acid receptor-β2 expression via DNA methylation. J. Gen. Virol. 2010; 91: 493-500.
30. Niu D, Zhang J, Ren Y et al. HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Mol. Oncol. 2009; 3: 67-76.
31. Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 1991; 7: 663-98.
32. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996; 10: 1-15.
33. Arbuthnot P, Capovilla A, Kew MC. The putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, and MAP kinase and JAK/STAT pathways. J. Gastroenterol. Hepatol. 2000; 15: 357-68.
34. Ye L, Dong N, Wang Q et al. Progressive changes in hepatoma cells stably transfected with hepatitis B virus x gene. Intervirology 2008; 51: 50-8.
35. Wang XW, Gibson MK, Vermeulen W et al. Abrogation of p53-induced apoptosis by the hepatitis B virus x gene. Cancer Rev. 1995; 55: 6012-16.
36. Elmore LW, Hancock AR, Chang SF et al. Hepatitis B virus x protein and p53 tumour suppressor interactions in the modulation of apoptosis. Proc. Natl. Acad. Sci. U S A 1997; 14: 707-12.
37. Lin Y, Nomura T, Yamashita T et al. The transactivation and p53-interacting functions of hepatitis B virus x protein are mutually interfering but distinct. Cancer Res. 1997; 57: 5137-42.
38. Ueda H, Ullrich SJ, Gangemi JD et al. Functional inactivation but not structural inactivation of p53 causes liver cancer. Nature (Genet) 1995; 9: 41-7.
39. Wang XW, Forrester K, Yeh H et al. Hepatitis B virus x protein inhibits p53 sequence-specific binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U S A 1994; 15: 2230-4.
40. Yi L, Kang-Park S, Do SI, Lee YI. The hepatitis B virus x protein activates a phosphatidylinositol 3-kinase -dependent survival signalling cascade. J. Biol. Chem. 2001; 276: 16969-77.
41. Cheng ASL, Yu J, Lai PB et al. COX-2 mediates hepatitis B virus x protein abrogation of p53-apoptosis. Biochem. Biophys. Res. Commun. 2008; 374: 175-80.
42. Kuo TC, Chao CCK. Hepatitis B virus x protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. Biochem. Pharmacol. 2010; 80: 1093-1102.
43. Terradillos O, Pollicino T, Lecouer H et al. P53-independent pro-apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17: 2115-23.
44. Kim H, Lee H, Yun Y. X gene product of hepatitis B virus induces apoptosis in liver cells. J. Biol. Chem. 1998; 273: 381-5.
45. Miao J, Chen GG, Chun SY et al. Hepatitis B virus x protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett. 2006; 236: 115-24.
46. Su F, Schneider RJ. Hepatitis B virus x protein sensitizes cells to apoptotic killing by tumour necrosis factor-α. Proc. Natl. Acad. Sci. U S A 1997; 94: 8744-9.
47. Cheng P, Li Y, Yang L et al. Hepatitis B virus x protein induces G2/M arrest and apoptosis through sustained actjivation of cyclinB1-CDK1 kinase. Oncol. Rep. 2009; 22: 1101-7.
48. Wang WH, Hullinger RL, Andrisani OM. Hepatitis B virus x protein via the p38MAPK pathway induces E3-2F1 release and ATR kinase activation mediating p53 apoptosis. J. Biol. Chem. 2008; 12: 25455-67.
49. Chan DW, Ng IO. Knock-down of hepatitis B virus x protein reduces the tumorigenicity of hepatocellular carcinoma cells. J. Pathol. 2006; 208: 372-80.
50. Liu YG, Liu SX, Liang XH et al. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem. Biophys. Res. Commun. 2007; 352: 329-4.
51. Tu H, Bonura C, Giannini C et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 2001; 61: 7803-10.
52. Zakim VA. Structure and function of telomeres. Annu. Rev. Genet. 1989; 23: 579-604.
53. Landblad V. DNA ends: maintenance of chromosome termini versus repair of double strand breaks. Mutat. Res. 2000; 451: 227-40.
54. Aviv A, Levy D, Mangel M. Growth, telomere dynamics and successful and unsuccessful human aging. Mech. Ageing Dev. 2003; 124: 829-37.
55. Counter CM, Avilion AA, LeFeuvre CF et al. Telomere shortening associated with chromosomal instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11: 1921-9.
56. Djojosubroto MW, Coi YS, Lee HW et al. Telomeres and telomerase in aging, regeneration, and cancer. Mol. Cells 2003; 15: 164-75.
57. Yokota T, Suda T, Igarashi M et al. Telomere length variation and maintenance in hepatocelluar carcinogenesis. Cancer 2003; 98: 110-18.
58. Satyanarayana A, Manna MP, Rudolph KL. Telomeres, telomerase and cancer: an endless search to target the ends. Cell Cycle 2004; 3: 1138-50.
59. Zhang X, Dong N, Zhang H et al. Effects of hepatitis B virus x protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J. Lab. Clin. Med. 2005; 145: 96-104.
60. Liu YC, Chen CVJ, Wu HS et al. Telomerase and c-myc expression in hepatocellular carcinomas. Eur. J. Surg. Oncol. 2004; 30: 380-90.
61. Su JM, Lai XM, Lan KH et al. X protein of hepatitis B virus functions as a transcriptional corepressor of the human telomerase promoter. Hepatology 2007; 46: 402-13.
62. Her S, Bell RA, Bloom AK et al. Phenylethanolamine N-methyltransferase gene expression. Sp1 and MAZ potential for tissue specific expression. J. Biol. Chem. 1999; 274: 8698-707.
63. Qu ZL, Zou SQ, Cui NQ et al. Up-regulation of human telomerase reverse transcriptase mRNA expression by in vitro transfection of hepatitis B virus x gene into human hepatocarcinoma and cholangiocarcinoma cells. World J. Gastroenterol. 2005; 11: 5627-32.
64. Saini N, Srinivasan R, Chawlay Y et al. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent on hepatitis virus status. Liver Int. 2009; 29: 1162-70.
65. Taylor EM, Lehmann AR. Conservation of eukarytotic DNA repair mechanisms. Int. J. Radiat. Biol. 1998; 74: 277-86.
66. Wood JW. Nucleotide excision repair in mammalian cells. J. Biol. Chem. 1997; 72: 23465-8.
67. Wang XW, Yeh H, Schaeffer L et al. P53 modulation of TFIIH-associated nucleotide excision repair activity. Nature 1995; 10: 188-95. 124.
68. Leveillard T, Andera L, Bissonnetti N et al. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 1996; 15: 1615-24. 10].
69. Bellamy CC, Clarke AR, Wyllie AH et al. P53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. FASEB J. 1997; 11: 591-9.
70. Becker SA, Lee TH, Butel JS et al. Hepatitis B virus x protein interferes with cellular DNA repair. J. Virol. 1998; 72: 266-72.
71. Lee TH, Elledge SJ, Butel JS. Hepatitis B virus x protein interacts with a probable cellular DNA repair protein. J. Virol. 1995; 69: 1107-14.
72. Capovilla A, Carmona S, Arbuthnot P. Hepatitis B virus x protein binds damaged DNA and sensitizes liver cells to ultraviolet irradiation. Biochem. Biophys. Res. Commun. 1997; 232: 255-60.
73. Qadri I, Conaway JW, Conaway RC et al. Hepatitis B virus transactivator protein, HBx, associates with components of TFIIH and stimulates the DNA helicase activity of TFIIH. Proc. Natl. Acad. Sci. U S A 1996; 93: 10578-83.
74. Groisman IJ, Koshy R, Henkler F et al. Down regulation of DNA excision repair by the HBx protein occurs in p53-proficient and 53 deficient cells. Carcinogenesis 1999; 20: 479-83.
75. Ko J, Prives C. p53: puzzle and paradigm. Genes Dev. 1996; 10: 1054-72.
76. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc. Natl. Acd. Sci. U S A 1995; 92: 11215-19.
77. Lee YI, Lee S, Lee Y et al. The human hepatitis B virus transactivator x gene product regulates Sp1-mediated transcription of an insulin like growth factor II promoter. Oncogene 1998; 16: 2367-80.
78. Madden CR, Finegold MJ, Slagle B. Altered DNA mutation spectrum in aflatoxin B1 treated transgenic mice that express the Hepatitis B virus x protein. J. Virol. 2002; 76: 11770-4.
79. Smith ML, Chen IT, Zhan Q et al. Involvement of the p53 tumour suppressor in repair of UV-type DNA damage. Oncogene 1995; 10: 1053-9.
80. Sirma H, Giannini C, Poussin K et al. Hepatitis B virus x mutants present in hepatocellular carcinoma tissue abrogate both the antiproliferative and the transactivation effects of HBx. Oncogene 1999; 18: 4848-59.
81. Ma NF, Lau SH, Hu L et al. COOH-truncated terminal HBV x protein plays key role in hepatocarcinogenesis. Clin. Cancer Res. 2008; 14: 5061-8.
82. Poussin K, Dienes H, Sirma H et al. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int. J. Cancer 1999; 192: 111-18.
83. Wang Y, Lau SH, Sham JST et al. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated x gene and hepatocellular carcinogenesis. Oncogene 2004; 23: 142-8.
84. Arii M, Takada S, Koike K. Identification of three essential regions of hepatitis B virus x protein for transactivation function. Oncogene 1992; 7: 397-403.
85. Kumar V, Jayasuryan N, Kumar R. A truncated mutant (residues 58-1400 of the hepatitis B virus x protein retains transactivating function. Proc. Natl. Acad. Sci. U S A 1996; 93: 5647-52.
86. Koike K. HBV DNA integration and insertional mutagenesis. In: Koshy R, Caselmann WH, eds. Hepatitis B Virus: Molecular Mechanisms in Disease and Novel Strategies for Therapy. London: Imperial College Press, 1998; Vol. 1. 133-60.
87. Liu X, Wang L, Zhang S et al. Mutations in the C-terminus of the x protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells cDNA microarray and proteomic analysis. Carcinogenesis 2008; 29: 1207-14.
88. Peifer M, Polakis P. Wnt signalling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000; 287: 1606-9.
89. Wong CM, Fan ST, Ng IOL. B-catenin mutation and over-expression in hepatocellular carcinoma. Clinico-pathologic and prognostic significance. Cancer 2001; 92: 136-45.
90. Wang Q, Zhang W, Liu Q et al. A mutant hepatitis B virus x protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipo-oxygenase and fatty acid synthase. Neoplasia 2010; 12: 103-15.
91. Schofield PN, Tate VE. Regulation of human IGFII transcription in foetal and adult tissues. Development 1987; 101: 793-803.
92. Deng T, Chen NL, Jia KM. A study of the relationship between expression of IGF-II, IGF-IIR, HBxAg and DNA ploidy, cell cycle of hepatocytes in hepatocellular carcinoma. Zhongua Nei Ke Za Zhi 1994; 33: 743-6.
93. Su Q, Liu YF, Zhang JF et al. Expression of insulin-like growth factor-II in hepatitis B cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 1994; 19: 788-99.
94. Kim SO, Park JG, Lee YI. Increased expression of insulin-like growth factor-I receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus x gene product. Cancer Res. 1996; 56: 3831-6.
95. Seo JH, Kim KW, Murakami S et al. Lack of co-localization of HBx and insulin-like growth factor II in the livers of patioents with chronic hepatitis B, cirrhosis and hepatocellular carcinoma. J. Korean Med. Sci. 1997; 12: 523-31.
96. Kang-Park S, Lee JH, Shin JH et al. Activation of the IGF-II gene by HBV protein requires PKC and p44/42 Map kinase signalings. Biochem. Biophys. Res. Commun. 2001; 283: 303-7.
97. Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocarcinomas. Nature 1991; 350: 427-8.
98. Bressac B, Kew MC, Wands J et al. Selective G to T mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1999; 350: 429-31.
99. Wang XW, Vermeulen W, Coursen JD et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 1996; 10: 1219-32.
100. Lee YI, Lee S, Das GC et al. Activation of the insulin-like growth factor II transcription by aflatoxin B1-induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 2000; 19: 3717-26.